Literature DB >> 22387836

[Guidelines for the management of ulcerative colitis].

Chang Hwan Choi1, Young-Ho Kim, You Sun Kim, Byong Duk Ye, Kang Moon Lee, Bo In Lee, Sung-Ae Jung, Won Ho Kim, Heeyoung Lee.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challenging issues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory Bowel Diseases (IBD) Study Group of Korean Association for the Study of Intestinal Diseases (KASID) set out the Korean guidelines for the management of UC. These guidelines are made by the adaptation using several foreign guidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatment guidelines for UC and will be revised with new evidences on treatment of UC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387836     DOI: 10.4166/kjg.2012.59.2.118

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  12 in total

1.  Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.

Authors:  Eun Soo Kim; Geun Am Song; Kwang Bum Cho; Kyung Sik Park; Kyeong Ok Kim; Byung Ik Jang; Eun Young Kim; Seong Woo Jeon; Hyun Seok Lee; Chang Heon Yang; Yong Kook Lee; Dong Wook Lee; Sung Kook Kim; Tae Oh Kim; Jonghun Lee; Hyung Wook Kim; Sam Ryong Jee; Seun Ja Park; Hyun Jin Kim
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

2.  Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity.

Authors:  Paul M Graham; Jason Z Li; Xueging Dou; Hong Zhu; Hara P Misra; Zhenquan Jia; Yunbo Li
Journal:  Mol Cell Biochem       Date:  2013-03-26       Impact factor: 3.396

Review 3.  The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?

Authors:  Rashid N S Lui; Siew C Ng
Journal:  Inflamm Intest Dis       Date:  2016-07-15

4.  Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.

Authors:  Ji Min Lee; Shu-Chen Wei; Kang-Moon Lee; Byong Duk Ye; Ren Mao; Hyun-Soo Kim; Soo Jung Park; Sang Hyoung Park; Eun Hye Oh; Jong Pil Im; Byung Ik Jang; Dae Bum Kim; Ken Takeuchi
Journal:  Gut Liver       Date:  2022-05-15       Impact factor: 4.321

5.  Vaccination and complementary and alternative medicine in patients with inflammatory bowel disease.

Authors:  Sung Bae Kim; Soo Jung Park; Sook Hee Chung; Kyu Yeon Hahn; Do Chang Moon; Sung Pil Hong; Jae Hee Cheon; Tae Il Kim; Won Ho Kim
Journal:  Intest Res       Date:  2014-04-29

6.  The effect of infliximab on patients with ulcerative colitis in Korea.

Authors:  Hyun Il Seo; Dong Il Park; Tae Oh Kim; You Sun Kim; Suck-Ho Lee; Ji Won Kim; Jae Hak Kim; Jeong Eun Shin
Journal:  Intest Res       Date:  2014-07-25

7.  Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis.

Authors:  Yoon Jee Lee; Jae Hee Cheon; Jae Hyun Kim; Sunho Yoo; Hyun Jung Lee; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

8.  Beneficial Effect of Herbal Formulation KM1608 on Inflammatory Bowl Diseases: A Preliminary Experimental Study.

Authors:  Myoung-Sook Shin; Sang-Back Kim; Jaemin Lee; Han-Seok Choi; Jimin Park; Jun Yeon Park; Sullim Lee; Gwi Seo Hwang; Bon Am Koo; Ki Sung Kang
Journal:  Molecules       Date:  2018-08-17       Impact factor: 4.411

9.  Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).

Authors:  Eun Soo Kim; Kyeong Ok Kim; Byung Ik Jang; Chang Kyun Lee; Hyo Jong Kim; Kang-Moon Lee; You Sun Kim; Chang Soo Eun; Sung-Ae Jung; Suk-Kyun Yang; Jun Lee; Tae-Oh Kim; Yunho Jung; Geom Seog Seo; Soon Man Yoon
Journal:  Gut Liver       Date:  2016-05-23       Impact factor: 4.519

10.  Cerebral venous thrombosis in a patient with Crohn's disease.

Authors:  Young-Hak Cho; Min Kyu Chae; Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Il Hyun Baek; Jung Won Jeon; Jun Uk Lim; In Taik Hong; Hye-Jin Ki; Jae Bin Kang
Journal:  Intest Res       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.